Want to see RDHL full AI Analyst Report?
RDHL Stock Chart & Stats
$1.20
-$0.32(-4.91%)
At close: 4:00 PM EST
$1.20
-$0.32(-4.91%)
Day’s Range― - ―
52-Week Range$0.64 - $3.31
Previous CloseN/A
Volume5.64K
Average Volume (3M)1.98M
Market Cap
$4.29M
Enterprise Value-$433.86K
Total Cash (Recent Filing)$2.87M
Total Debt (Recent Filing)$214.00K
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding6,080,920
10 Day Avg. Volume104,605
30 Day Avg. Volume1,981,143
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.76
Price to Sales (P/S)11.38
P/FCF Ratio-0.34
Enterprise Value/Market Cap-0.10
Enterprise Value/Revenue-0.05
Enterprise Value/Gross Profit-0.07
Enterprise Value/Ebitda0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)$50.60M
Bulls Say, Bears Say
Bulls Say
Improved Leverage And Positive EquityLeverage materially improved versus prior years with total debt reduced to roughly $1.1M and equity flipping positive to about $4.3M on assets of ~$25.3M. This stronger solvency profile improves runway and strategic optionality for M&A or partnerships over the next 2–6 months.
Opaganib Regulatory Momentum And Preclinical SupportRare pediatric disease designation (complementing orphan status) and AACR preclinical data bolster opaganib’s regulatory and clinical value. These durable regulatory advantages can accelerate development, attract partners, and enhance commercial potential in pediatric oncology and biodefense applications.
Portfolio Restructuring And Commercial PartnershipsSpinning Talicia into a co-commercial vehicle, securing a Cumberland stake and added Humana Part D coverage diversifies commercialization risk and revenue pathways. Licensing deals and focused R&D sharpen the company’s go‑to‑market model and reduce single-product concentration over time.
Bears Say
Severe Revenue CollapseA dramatic top-line decline erodes the company’s commercial foundation and recurring revenue base. With almost all product sales evaporating year-over-year, sustaining fixed infrastructure, retaining commercial partners, and funding pipeline activities without meaningful new revenues becomes materially harder over the medium term.
Persistent Negative Operating Cash FlowDeep, consistent operating cash burn demonstrates weak cash generation and continued funding dependence. Ongoing negative OCF constrains discretionary R&D or commercial investment, forces management to prioritize financing or asset sales, and raises execution risk absent durable revenue recovery.
Heavy Reliance On Equity Financing (dilution Risk)Frequent use of ATM programs and private placements to plug funding gaps transfers financing risk to shareholders via dilution. Reliance on market financing limits strategic flexibility, can raise investor resistance to future raises, and may impair long‑term capital structure stability if cash generation does not improve.
RedHill Biopharma News
RDHL FAQ
What was RedHill Biopharma’s price range in the past 12 months?
RedHill Biopharma lowest stock price was $0.64 and its highest was $3.31 in the past 12 months.
What is RedHill Biopharma’s market cap?
RedHill Biopharma’s market cap is $4.29M.
When is RedHill Biopharma’s upcoming earnings report date?
RedHill Biopharma’s upcoming earnings report date is Aug 20, 2026 which is in 31 days.
How were RedHill Biopharma’s earnings last quarter?
Currently, no data Available
Is RedHill Biopharma overvalued?
According to Wall Street analysts RedHill Biopharma’s price is currently Overvalued.
Does RedHill Biopharma pay dividends?
RedHill Biopharma does not currently pay dividends.
What is RedHill Biopharma’s EPS estimate?
RedHill Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RedHill Biopharma have?
RedHill Biopharma has 6,080,920 shares outstanding.
What happened to RedHill Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of RedHill Biopharma?
Currently, no hedge funds are holding shares in RDHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RedHill Biopharma
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
Technical Analysis
China Pharma Holdings
―
Sonoma Pharmaceuticals
―
PainReform
―
Universe Pharmaceuticals
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
― Insiders
―
Mutual Funds
9.25% Other Institutional Investors
90.75% Public Companies and
Individual Investors